NYSE:PFE - Pfizer Stock Price, Price Target & More

Get Started

$35.68 -0.21 (-0.59 %)

(As of 05/27/2018 01:27 PM ET)

Previous Close$35.68

Today's Range$35.5442 - $35.92

52-Week Range$31.67 - $39.43

Volume14.24 million shs

Average Volume21.41 million shs

Market Capitalization$212.40 billion

P/E Ratio13.46

Dividend Yield3.81%

Beta0.89

About Pfizer (NYSE:PFE)

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:PFE

CUSIP71708110

Webwww.pfizer.com

Phone212-733-2323

Debt

Debt-to-Equity Ratio0.45

Current Ratio1.27

Quick Ratio0.98

Price-To-Earnings

Trailing P/E Ratio13.46

Forward P/E Ratio12.09

P/E Growth1.77

Sales & Book Value

Annual Sales$52.55 billion

Price / Sales4.04

Cash Flow$3.7518 per share

Price / Cash9.51

Book Value$11.85 per share

Price / Book3.01

Profitability

EPS (Most Recent Fiscal Year)$2.65

Net Income$21.31 billion

Net Margins41.29%

Return on Equity25.29%

Return on Assets9.78%

Miscellaneous

Employees90,200

Outstanding Shares5,952,870,000

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Thursday, April 26th. Stockholders of record on Friday, May 11th will be given a dividend of $0.34 per share on Friday, June 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.81%. The ex-dividend date of this dividend is Thursday, May 10th. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has approved a stock repurchase plan on Tuesday, December 19th 2017, which authorizes the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.74 by $0.03. The biopharmaceutical company earned $12.91 billion during the quarter, compared to analysts' expectations of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business's quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

What price target have analysts set for PFE?

20 brokerages have issued 1-year target prices for Pfizer's stock. Their forecasts range from $36.00 to $43.50. On average, they anticipate Pfizer's stock price to reach $40.2059 in the next year. View Analyst Ratings for Pfizer.

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in May. As of May 15th, there was short interest totalling 63,688,761 shares, an increase of 2.7% from the April 30th total of 65,448,096 shares. Based on an average daily trading volume, of 24,821,410 shares, the short-interest ratio is currently 2.6 days. Currently, 1.1% of the company's shares are sold short.

Who are some of Pfizer's key competitors?

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Bayer (BAYRY), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

Mr. Ian C. Read, Chairman & CEO (Age 64)
Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Has Pfizer been receiving favorable news coverage?

News coverage about PFE stock has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pfizer earned a daily sentiment score of 0.10 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.72%), Northern Trust Corp (1.31%), Massachusetts Financial Services Co. MA (1.04%), Dimensional Fund Advisors LP (0.79%), Franklin Resources Inc. (0.75%) and Barrow Hanley Mewhinney & Strauss LLC (0.69%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Swiss National Bank, FIL Ltd, Caisse DE Depot ET Placement DU Quebec, Levin Capital Strategies L.P., MUFG Securities EMEA plc and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., Neuberger Berman Group LLC, Mackay Shields LLC, Teacher Retirement System of Texas, LSV Asset Management and Summit Trail Advisors LLC. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $35.68.

How big of a company is Pfizer?

Pfizer has a market capitalization of $212.40 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		970 (Vote Outperform)
Underperform Votes:		527 (Vote Underperform)
Total Votes:		1,497

MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Pfizer (NYSE:PFE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

20 Wall Street analysts have issued ratings and price targets for Pfizer in the last 12 months. Their average twelve-month price target is $40.2059, suggesting that the stock has a possible upside of 12.68%. The high price target for PFE is $43.50 and the low price target for PFE is $36.00. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.35	2.37	2.42	2.56
Ratings Breakdown:	2 Sell Rating(s) 9 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 10 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 9 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$40.2059	$39.2222	$39.3889	$38.5625
Price Target Upside:	12.68% upside	7.99% upside	6.89% upside	8.66% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/18/2018	Credit Suisse Group	Reiterated Rating	Neutral	$39.00	Low
5/14/2018	Jefferies Group	Reiterated Rating	Neutral	$39.00	Low
5/8/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$42.00	Low
5/3/2018	DZ Bank	Reiterated Rating	Sell		Low
5/2/2018	Morningstar	Set Price Target	Buy	$43.50	Low
5/2/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$43.00 ➝ $42.00	Low
4/12/2018	Citigroup	Reiterated Rating	Sell		Medium
4/11/2018	Berenberg Bank	Reiterated Rating	Neutral	$37.00	Low
4/5/2018	Barclays	Downgrade	Overweight ➝ Equal Weight	$41.00 ➝ $38.00	Medium
1/31/2018	Leerink Swann	Boost Price Target	Market Perform ➝ Market Perform	$35.00 ➝ $38.00	Medium
1/31/2018	UBS	Set Price Target	Buy	$42.00	Medium
1/31/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Buy	$41.00 ➝ $43.00	Medium
1/31/2018	Societe Generale	Set Price Target	Neutral	$40.00	Medium
1/30/2018	Goldman Sachs Group	Set Price Target	Neutral	$36.00	High
1/30/2018	Bank of America	Set Price Target	Buy	$40.00	Medium
1/30/2018	Sanford C. Bernstein	Set Price Target	Buy	$43.00	Low
1/29/2018	SunTrust Banks	Reiterated Rating	Hold ➝ Hold	$33.00 ➝ $40.00	Low
1/2/2018	Nord/LB	Reiterated Rating	Neutral		Low
12/6/2017	Deutsche Bank	Set Price Target	Buy	$38.00	Low
8/14/2017	Cowen	Set Price Target	Buy	$43.00	Low
2/1/2017	Atlantic Securities	Set Price Target	Buy	$37.00	N/A
1/21/2017	Piper Jaffray Companies	Set Price Target	Buy	$53.00	N/A
12/2/2016	Guggenheim	Initiated Coverage	Neutral		N/A
11/2/2016	Argus	Downgrade	Buy ➝ Hold		N/A

(Data available from 5/27/2016 forward)

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Earnings Estimates

2018 EPS Consensus Estimate: $2.95

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.67	$0.75	$0.72
Q2 2018	2	$0.70	$0.77	$0.74
Q3 2018	2	$0.75	$0.79	$0.77
Q4 2018	2	$0.64	$0.82	$0.73

Pfizer (NYSE PFE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/30/2018		$0.74					N/A
5/1/2018	Q1 2018	$0.74	$0.77	$13.1381 billion	$12.9060 billion	View	N/A
1/30/2018	Q4 2017	$0.5620	$0.62	$13.6746 billion	$13.7030 billion	View	Listen
10/31/2017	Q3 2017	$0.65	$0.67	$13.1749 billion	$13.1680 billion	View	N/A
8/1/2017	Q2 2017	$0.65	$0.67	$13.0774 billion	$12.8960 billion	View	Listen
5/2/2017	Q1 2017	$0.67	$0.69	$13.0890 billion	$12.7790 billion	View	Listen
1/31/2017	Q416	$0.50	$0.47	$13.64 billion	$13.60 billion	View	N/A
11/1/2016	Q3	$0.62	$0.61	$13.05 billion	$13.05 billion	View	N/A
8/2/2016	Q216	$0.62	$0.64	$13.01 billion	$13.10 billion	View	N/A
5/3/2016	Q116	$0.55	$0.67	$12.00 billion	$13.00 billion	View	N/A
2/2/2016	Q415	$0.52	$0.53	$13.57 billion	$14.05 billion	View	N/A
10/27/2015	Q315	$0.51	$0.60	$11.56 billion	$12.10 billion	View	Listen
7/28/2015	Q215	$0.52	$0.56	$11.39 billion	$11.00 billion	View	Listen
4/28/2015	Q115	$0.49	$0.51	$10.79 billion	$10.86 billion	View	N/A
1/27/2015	Q414	$0.53	$0.54	$12.94 billion	$13.10 billion	View	N/A
10/28/2014	Q314	$0.55	$0.57	$12.24 billion	$12.40 billion	View	N/A
7/29/2014	Q214	$0.57	$0.58	$12.49 billion	$12.80 billion	View	N/A
5/5/2014	Q114	$0.56	$0.57	$12.07 billion	$11.35 million	View	N/A
1/27/2014	Q413	$0.52	$0.56	$13.35 billion	$13.56 billion	View	N/A
10/29/2013	Q313	$0.56	$0.58	$12.69 billion	$12.64 billion	View	N/A
7/30/2013	Q2 2013	$0.55	$0.56	$13.02 billion	$12.97 billion	View	Listen
4/30/2013	Q1 2013	$0.55	$0.54	$14.10 billion	$13.50 billion	View	Listen
1/29/2013	Q4 2012	$0.44	$0.47	$14.40 billion	$15.10 billion	View	Listen
11/1/2012	Q312	$0.53	$0.53	$14.64 billion	$14.00 billion	View	N/A
7/31/2012		$0.54	$0.62			View	N/A
5/1/2012		$0.57	$0.58			View	N/A
1/31/2012		$0.47	$0.50			View	N/A
11/1/2011		$0.55	$0.62			View	N/A
8/2/2011		$0.59	$0.60			View	N/A
5/3/2011		$0.59	$0.60			View	N/A
2/1/2011		$0.46	$0.47			View	N/A
11/2/2010	Q3 2010	$0.51	$0.54			View	N/A
8/3/2010	Q2 2010	$0.52	$0.62			View	N/A
5/4/2010	Q1 2010	$0.53	$0.60			View	N/A
2/3/2010	Q4 2009	$0.49	$0.49			View	N/A
10/20/2009	Q3 2009	$0.48	$0.51			View	N/A
7/22/2009	Q2 2009	$0.46	$0.48			View	N/A
4/28/2009	Q1 2009	$0.48	$0.54			View	N/A
1/26/2009	Q4 2008	$0.60	$0.65			View	N/A
10/21/2008	Q3 2008	$0.60	$0.62			View	N/A
7/23/2008	Q2 2008	$0.54	$0.55			View	N/A
4/17/2008	Q1 2008	$0.65	$0.61			View	N/A
1/23/2008	Q4 2007	$0.47	$0.52			View	N/A

(Earnings results data provided by Zacks Investment Research)

Pfizer (NYSE:PFE) Dividend Information

Pfizer pays an annual dividend of $1.36 per share, with a dividend yield of 3.81%. PFE's next quarterly dividend payment will be made on Friday, June 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 7.20% each year. Pfizer pays out 51.32% of its earnings out as a dividend.

Next Dividend:	6/1/2018
Annual Dividend:	$1.36
Dividend Yield:	3.81%
Dividend Growth:	7.20% (3 Year Average)
Payout Ratio(s):	51.32% (Trailing 12 Months of Earnings) 46.10% (Based on This Year's Estimates) 44.59% (Based on Next Year's Estimates) 36.25% (Based on Cash Flow)
Track Record:	8 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/26/2018	quarterly	$0.34	3.67%	5/10/2018	5/11/2018	6/1/2018
12/18/2017	quarterly	$0.34	3.68%	2/1/2018	2/2/2018	3/1/2018
9/27/2017	quarterly	$0.32	3.6%	11/9/2017	11/10/2017	12/1/2017
6/22/2017	quarterly	$0.32	3.75%	8/2/2017	8/4/2017	9/1/2017
4/28/2017	quarterly	$0.32	3.77%	5/10/2017	5/12/2017	6/1/2017
12/12/2016	quarterly	$0.32	3.9%	2/1/2017	2/3/2017	3/1/2017
9/23/2016	quarterly	$0.30	3.5%	11/8/2016	11/11/2016	12/1/2016
6/23/2016	quarterly	$0.30	3.53%	8/3/2016	8/5/2016	9/1/2016
4/28/2016	quarterly	$0.30	3.67%	5/11/2016	5/13/2016	6/1/2016
12/14/2015	quarterly	$0.30	3.72%	2/3/2016	2/5/2016	3/2/2016
9/25/2015	quarterly	$0.28	3.63%	11/4/2015	11/6/2015	12/1/2015
6/25/2015	quarterly	$0.28	3.3%	8/5/2015	8/7/2015	9/2/2015
4/23/2015	quarterly	$0.28	3.18%	5/6/2015	5/8/2015	6/2/2015
12/15/2014	quarterly	$0.28	3.65%	2/4/2015	2/6/2015	3/3/2015
10/23/2014	quarterly	$0.26	3.57%	11/5/2014	11/7/2014	12/2/2014
6/26/2014	quarterly	$0.26	3.51%	7/30/2014	8/1/2014	9/3/2014
4/25/2014	quarterly	$0.26	3.38%	5/7/2014	5/9/2014	6/3/2014
12/16/2013	quarterly	$0.26	3.45%	2/5/2014	2/7/2014	3/4/2014
10/24/2013	quarterly	$0.24	3.14%	11/6/2013	11/8/2013	12/3/2013
6/27/2013	quarterly	$0.24	3.43%	7/31/2013	8/2/2013	9/4/2013
4/25/2013	quarterly	$0.24	3.19%	5/8/2013	5/10/2013	6/4/2013
12/17/2012	quarterly	$0.24	3.74%	1/30/2013	2/1/2013	3/5/2013

(Data available from 1/1/2013 forward)

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 69.53%

Insider Trading History for Pfizer (NYSE:PFE)

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2018	Ian C Read	CEO	Sell	132,312	$36.01	$4,764,555.12
3/13/2018	Douglas M Lankler	Insider	Sell	50,000	$36.89	$1,844,500.00	133,057
3/13/2018	Rady A Johnson	EVP	Sell	27,323	$36.55	$998,655.65	70,332
3/9/2018	Mikael Dolsten	Insider	Sell	69,699	$36.59	$2,550,286.41	120,784
3/6/2018	Charles H Hill	Insider	Sell	42,393	$35.76	$1,515,973.68
3/2/2018	Mikael Dolsten	Insider	Sell	13,986	$35.85	$501,398.10	120,884
2/27/2018	Sally Susman	EVP	Sell	33,368	$37.03	$1,235,617.04	191,505
2/27/2018	W Don Cornwell	Director	Sell	1,758	$36.79	$64,676.82	1,000
2/26/2018	Kirsten Lund-Jurgensen	Insider	Sell	9,510	$37.19	$353,676.90	36,959
12/15/2017	Alexander R Mackenzie	Insider	Sell	6,750	$37.00	$249,750.00	103,458
12/15/2017	Rady A Johnson	EVP	Sell	8,000	$37.07	$296,560.00	46,963
11/1/2017	Alexander R Mackenzie	Insider	Sell	14,700	$35.30	$518,910.00	117,432
10/2/2017	Alexander R Mackenzie	EVP	Sell	7,350	$35.65	$262,027.50	117,432
9/12/2017	Sally Susman	Insider	Sell	38,230	$35.00	$1,338,050.00	145,649
9/1/2017	Alexander R Mackenzie	Insider	Sell	7,350	$34.00	$249,900.00	124,774
8/31/2017	Alexander R Mackenzie	Insider	Sell	7,350	$34.00	$249,900.00	132,124
8/31/2017	Frank A Damelio	EVP	Sell	94,409	$34.00	$3,209,906.00	337,389
8/31/2017	Ian C Read	CEO	Sell	197,168	$34.00	$6,703,712.00	580,318
8/21/2017	Laurie J Olson	Insider	Sell	8,064	$32.70	$263,692.80	74,506
8/7/2017	Alexander R Mackenzie	Insider	Sell	15,000	$33.50	$502,500.00	151,474
8/4/2017	Ian C. Read	CEO	Sell	96,950	$34.00	$3,296,300.00
3/10/2017	Rady A Johnson	Insider	Sell	4,500	$34.19	$153,855.00	54,963
3/9/2017	Charles H Hill	Insider	Sell	36,000	$34.07	$1,226,520.00	57,329
3/2/2017	Mikael Dolsten	Insider	Sell	30,970	$34.51	$1,068,774.70	64,719
11/9/2016	Anthony J Maddaluna	Insider	Sell	10,000	$33.00	$330,000.00	112,087
11/4/2016	Albert Bourla	Insider	Sell	18,390	$30.05	$552,619.50	149,199
5/26/2016	Frank A Damelio	EVP	Sell	100,000	$34.49	$3,449,000.00	472,994
5/24/2016	Loretta V Cangialosi	VP	Sell	86,000	$33.97	$2,921,420.00	271,663
5/11/2016	Laurie J Olson	EVP	Sell	4,700	$33.50	$157,450.00	71,659
5/10/2016	Frank A Damelio	EVP	Sell	192,000	$33.66	$6,462,720.00	564,994
5/10/2016	John D Young	Insider	Sell	41,700	$33.53	$1,398,201.00	200,399
5/9/2016	Anthony J Maddaluna	EVP	Sell	8,950	$33.75	$302,062.50	88,922
5/9/2016	Ian C Read	CEO	Sell	275,000	$33.80	$9,295,000.00	1,446,738
5/5/2016	Sally Susman	EVP	Sell	76,116	$33.75	$2,568,915.00	195,951
5/4/2016	Douglas M Lankler	EVP	Sell	29,700	$33.69	$1,000,593.00	124,920
5/4/2016	Mikael Dolsten	Insider	Sell	67,588	$33.46	$2,261,494.48	438,107
5/3/2016	Frank A Damelio	EVP	Sell	87,079	$33.65	$2,930,208.35	372,994
10/6/2015	Pfizer Inc	major shareholder	Buy	714,285	$7.00	$4,999,995.00	2,489,364
6/11/2015	Laurie J Olson	EVP	Sell	26,000	$34.39	$894,140.00
3/12/2015	Sally Susman	EVP	Sell	46,179	$34.00	$1,570,086.00
2/13/2015	Loretta V Cangialosi	VP	Sell	104,000	$34.73	$3,611,920.00
2/12/2015	Anthony J Maddaluna	EVP	Sell	9,000	$34.85	$313,650.00
2/11/2015	Frank A Damelio	EVP	Sell	14,800	$34.30	$507,640.00
2/10/2015	Anthony J Maddaluna	EVP	Sell	9,000	$33.78	$304,020.00
12/8/2014	Anthony J Maddaluna	EVP	Sell	6,500	$32.00	$208,000.00
11/10/2014	Charles H Hill	EVP	Sell	8,285	$30.18	$250,041.30
11/7/2014	John D Young	Insider	Sell	21,600	$29.89	$645,624.00
10/29/2014	Anthony J Maddaluna	EVP	Sell	2,425	$29.56	$71,683.00
6/12/2014	Laurie J Olson	EVP	Sell	36,275	$29.53	$1,071,200.75
6/2/2014	Geno J Germano	Insider	Sell	30,000	$29.68	$890,400.00
3/17/2014	John Young	Insider	Sell	9,000	$31.38	$282,420.00	99,647
3/4/2014	Loretta Cangialosi	VP	Sell	102,943	$32.05	$3,299,323.15	171,756
3/4/2014	Mikael Dolsten	Insider	Sell	35,789	$32.58	$1,166,005.62	344,571
3/4/2014	Sally Susman	EVP	Sell	67,585	$32.59	$2,202,595.15	173,637
1/13/2014	Frank Damelio	EVP	Sell	131,810	$30.82	$4,062,384.20	356,451
11/1/2013	Anthony J Maddaluna	EVP	Sell	43,500	$31.02	$1,349,370.00
11/1/2013	Loretta V Cangialosi	VP	Sell	10,000	$31.20	$312,000.00
10/28/2013	Ian C Read	CEO	Sell	338,000	$30.57	$10,332,660.00
9/16/2013	Freda Lewis-Hall	EVP	Sell	38,461	$28.70	$1,103,830.70	118,383
7/31/2013	Charles H Hill	EVP	Sell	96,500	$29.64	$2,860,260.00
7/31/2013	Loretta V Cangialosi	VP	Sell	14,688	$29.63	$435,205.44
5/15/2013	Amy W Schulman	EVP	Sell	70,000	$29.36	$2,055,200.00
5/15/2013	Ian C Read	CEO	Sell	69,900	$29.39	$2,054,361.00

(Data available from 1/1/2013 forward)

Pfizer (NYSE PFE) News Headlines

Source:

Date	Headline
	Pfizer executives are changing their tune on an approach for a promising new way to treat cancer, and it could be where the field is headed (PFE) www.msn.com - May 27 at 11:06 AM
	Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities www.wsj.com - May 26 at 10:16 AM
	$13.28 Billion in Sales Expected for Pfizer Inc. (PFE) This Quarter www.americanbankingnews.com - May 26 at 3:30 AM
	Pfizer's Tafamadis Gets Breakthrough Therapy Designation finance.yahoo.com - May 25 at 10:19 AM
	Pfizer To Pay $23.85 Mln To Resolve Kickback Claims: DoJ www.nasdaq.com - May 25 at 10:19 AM
	Pfizer's Tafamidis a Breakthrough Therapy for rare heart disorder seekingalpha.com - May 25 at 10:19 AM
	Pfizer’s Products with Declining Revenues in Q1 2018 finance.yahoo.com - May 25 at 10:19 AM
	Pfizer to pay $23.85 mln to resolve US kickbacks case www.reuters.com - May 24 at 3:41 PM
	Pfizer executives are changing their tune on an approach for a promising new way to treat cancer, and it could be ... www.businessinsider.com - May 24 at 3:41 PM
	Pfizer to pay $23.9 million to resolve US kickbacks case www.cnbc.com - May 24 at 3:41 PM
	[$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities finance.yahoo.com - May 24 at 3:41 PM
	Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says finance.yahoo.com - May 24 at 3:41 PM
	Pfizer to pay $23.85 million to settle kickback allegations finance.yahoo.com - May 24 at 3:41 PM
	Pfizer agrees to pay nearly $24m to settle kickback claims www.ft.com - May 24 at 10:45 AM
	Pfizer’s Growth Drivers in Q1 2018 finance.yahoo.com - May 24 at 10:45 AM
	3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More investorplace.com - May 24 at 10:36 AM
	$0.75 EPS Expected for Pfizer (PFE) This Quarter www.americanbankingnews.com - May 24 at 10:19 AM
	EpiPen shortage heaps pressure on Pfizer seekingalpha.com - May 24 at 3:30 AM
	Strata Oncology Secures $26 Million in Series B Funding, Led by Pfizer and Merck www.prnewswire.com - May 23 at 3:37 PM
	More Than 200 Critical Drugs May Not Be There When You Need Them fortune.com - May 23 at 3:37 PM
	Brainstorm Health: ADHD and Overdoses, Pfizer and the Drug Supply Chain, Geisinger DNA Testing fortune.com - May 23 at 10:05 AM
	Critical Condition: Inside Pfizer's Drug Supply Problem fortune.com - May 23 at 10:05 AM
	Better Buy: AbbVie Inc. vs. Pfizer Inc. finance.yahoo.com - May 23 at 10:05 AM
	FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy finance.yahoo.com - May 23 at 10:05 AM
	A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+ finance.yahoo.com - May 22 at 3:40 PM
	Spark Therapeutics (ONCE) and Pfizer (PFE) Highlight Data from Ongoing Phase 1/2 Clinical Trial of Investigational ... www.streetinsider.com - May 22 at 10:21 AM
	Pfizer Begins Phase 1/2 Study To Evaluate Respiratory Syncytial Virus Vaccine www.nasdaq.com - May 22 at 10:21 AM
	BRIEF-Pfizer Begins Phase 1/2 Study To Evaluate Respiratory Syncytial Virus Vaccine www.reuters.com - May 22 at 10:21 AM
	Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine www.businesswire.com - May 22 at 10:21 AM
	Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and ... globenewswire.com - May 22 at 10:21 AM
	Pfizer (PFE) Begins a Phase 1/2 Study to Evaluate RSV Vaccine www.streetinsider.com - May 22 at 10:21 AM
	Gauging the Upside Potential of Vertex Pharmaceuticals Stock finance.yahoo.com - May 22 at 10:21 AM
	GlaxoSmithKline (GSK) with Pfizer (PFE) Reports ViiV Healthcare Granted EU Marketing Authorisation for Juluca ... www.streetinsider.com - May 21 at 10:30 AM
	Credit Suisse Group Analysts Give Pfizer (PFE) a $39.00 Price Target www.americanbankingnews.com - May 18 at 4:17 PM
	Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study www.zacks.com - May 18 at 3:40 PM
	Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug finance.yahoo.com - May 18 at 3:40 PM
	Eli Lilly’s Valuation on May 17 finance.yahoo.com - May 18 at 3:40 PM
	Pfizer's Lyrica successful in late-stage pediatric epilepsy study seekingalpha.com - May 17 at 3:35 PM
	Pfizer: Lyrica Oral Solution CV Phase 3 Trial Meets Primary Endpoint www.nasdaq.com - May 17 at 3:35 PM
	Roche's Alecensa beats Pfizer's Xalkori in late-stage lung cancer study seekingalpha.com - May 17 at 10:47 AM
	BRIEF-Trial shows Pfizer's Lyrica reduces seizures in children with epilepsy www.reuters.com - May 17 at 10:47 AM
	Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO www.businesswire.com - May 17 at 10:47 AM
	Exelixis Is Expected to Report a Robust Revenue Rise in 2018 finance.yahoo.com - May 17 at 10:47 AM
	Roche Tecentriq Combo Achieves Longer Overall Survival Rate finance.yahoo.com - May 17 at 10:47 AM
	Sangamo Therapeutics Stock History finance.yahoo.com - May 17 at 10:47 AM
	Taking Stock of Gilead Sciences’ Key Developments finance.yahoo.com - May 17 at 10:47 AM
	Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar www.zacks.com - May 16 at 11:07 AM
	Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar finance.yahoo.com - May 16 at 11:06 AM
	BRIEF-Pfizer'S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By US FDA www.reuters.com - May 15 at 3:37 PM
	Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod finance.yahoo.com - May 15 at 3:37 PM